The management of gastrointestinal symptoms in Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 12, Issue 2, 2012, Pages 239-248

  Salat Foix, David ^a   Suchowersky, Oksana ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

assessment; autonomic dysfunction; gastrointestinal tract; Parkinson's disease; pathophysiology; symptoms; treatment

Indexed keywords

AMANTADINE; AMITRIPTYLINE; ANALGESIC AGENT; ATROPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; COLCHICINE; DOMPERIDONE; ERYTHROMYCIN; GLYCOPYRRONIUM BROMIDE; IPRATROPIUM BROMIDE; ISPAGULA; LOPERAMIDE; MACROGOL; MAGNESIUM OXIDE; MISOPROSTOL; MODAFINIL; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; PROKINETIC AGENT; TETRACYCLIC ANTIDEPRESSANT AGENT; TYROSINE 3 MONOOXYGENASE;

ABDOMINAL PAIN; CLINICAL PRACTICE; CONSTIPATION; DORSAL NORADRENERGIC BUNDLE; DYSKINESIA; DYSPEPSIA; ELECTROCARDIOGRAM; FECES INCONTINENCE; FLUID INTAKE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT FUNCTION; HUMAN; HYPERSALIVATION; LEWY BODY; MOOD DISORDER; NERVE CELL; NERVE STIMULATION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; QUALITY OF LIFE; RATING SCALE; REVIEW; SCINTIGRAPHY; SENSORY NERVE; SEROTYPE; STOMACH EMPTYING; UNSPECIFIED SIDE EFFECT; VAGUS NERVE DORSAL NUCLEUS; VALIDATION STUDY;

AUTONOMIC NERVOUS SYSTEM; CONSTIPATION; DEGLUTITION DISORDERS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; PARKINSON DISEASE; SIALORRHEA;

EID: 84856594495     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.192     Document Type: Review

References (91)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55(3), 181-184 (1992).
2. Muzerengi S, Contrafatto D, Chaudhuri KR. Non-motor symptoms: identification and management. Parkinsonism Relat. Disord. 13(Suppl. 3), S450-S456 (2007). (Pubitemid 351215285)
3. Muangpaisan W, Mathews A, Hori H, Seidel D. A systematic review of the worldwide prevalence and incidence of Parkinson's disease. J. Med. Assoc. Thai. 94(6), 749-755 (2011).
4. Shulman LM. Gender differences in Parkinson's disease. Gend. Med. 4(1), 8-18 (2007). (Pubitemid 46917063)
5. Gasser T, Hardy J, Mizuno Y. Milestones in PD genetics. Mov. Disord. 26(6), 1042-1048 (2011).
6. Elbaz A, Tranchant C. Epidemiologic studies of environmental exposures in Parkinson's disease. J. Neurol. Sci. 262(1-2), 37-44 (2007). (Pubitemid 47398893)
7. Khusnutdinova E, Gilyazova I, Ruiz-Pesini E, et al. A mitochondrial etiology of neurodegenerative diseases: evidence from Parkinson's disease. Ann. NY Acad. Sci. 1147, 1-20 (2008).
8. Dickson DW, Fujishiro H, Orr C, et al. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat. Disord. 15(Suppl. 3), S1-S5 (2009).
9. Gárdián G, Vécsei L. Medical treatment of Parkinson's disease: today and the future. Int. J. Clin. Pharmacol. Ther. 48(10), 633-642 (2010).
10. Kyle G. The physical, social and emotional effects of bowel dysfunction in Parkinson's disease. Nurs. Times 106(33), 20-22 (2010).
11. Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov. Disord. 20(6), 726-733 (2005). (Pubitemid 41051784)
12. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov. Disord. 25(6), 697-701 (2010).
13. Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov. Disord. 23(8), 1065-1075 (2008).
14. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of PD: refining the diagnostic criteria. Lancet Neurol. 8(12), 1150-1157 (2009).
15. Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology 87(4), 848-856 (1984). (Pubitemid 14040457)
16. Singaram C, Ashraf W, Gaumnitz EA, et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 346(8979), 861-864 (1995).
17. Phillips RJ, Walter GC, Wilder SL, et al. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease? Neuroscience 153(3), 733-750 (2008).
18. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol. 79(6), 581-583 (1990). (Pubitemid 20170333)
19. Greene JG, Noorian AR, Srinivasan S. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of PD. Exp. Neurol. 218(1), 154-161 (2009).
20. Drolet RE, Cannon JR, Montero L, Greenamyre JT. Chronic rotenone exposure reproduces PD gastrointestinal neuropathology. Neurobiol. Dis. 36(1), 96-102 (2009).
21. Blandini F, Balestra B, Levandis G, et al. Functional and neurochemical changes of the gastrointestinal tract in a rodent model of PD. Neurosci. Lett. 467(3), 203-207 (2009).
22. Kuo YM, Li Z, Jiao Y, et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum. Mol. Genet. 19(9), 1633-1650 (2010).
23. Tian YM, Chen X, Luo DZ, et al. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease. Neuroscience 153(3), 634-644 (2008).
24. Chaumette T, Lebouvier T, Aubert P, et al. Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. Neurogastroenterol. Motil. 21(2), 215-222 (2009).
25. Anderson G, Noorian AR, Taylor G, et al. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease. Exp. Neurol. 207(1), 4-12 (2007). (Pubitemid 47332479)
26. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol. Appl. Neurobiol. 33(6), 599-614 (2007). (Pubitemid 350076090)
27. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2(2), 107-116 (2003). (Pubitemid 37443331)
28. Natale G, Pasquali L, Ruggieri S, Paparelli A, Fornai F. Parkinson's disease and the gut: a well known clinical association in need of an effective cure and explanation. Neurogastroenterol. Motil. 20(7), 741-749 (2008). (Pubitemid 351814395)
29. Jost WH. Gastrointestinal dysfunction in Parkinson's Disease. J. Neurol. Sci. 289(1-2), 69-73 (2010).
30. Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of PD: meta-analysis of randomized controlled trials. Drug Saf. 33(2), 147-161 (2010).
31. Abbott RD, Ross GW, White LR, et al. Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J. Neurol. 250(Suppl. 3), III30-III39 (2003).
32. Savica R, Carlin JM, Grossardt BR, et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 73(21), 1752-1758 (2009).
33. Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson's disease. Parkinsonism Relat. Disord. 13(Suppl.), S2-S7 (2007). (Pubitemid 47444539)
34. Marras C, Schuele B, Munhoz RP, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 77(4), 325-333 (2011).
35. Krygowska-Wajs A, Cheshire WP Jr, Wszolek ZK, et al. Evaluation of gastric emptying in familial and sporadic Parkinson disease. Parkinsonism Relat. Disord. 15(9), 692-696 (2009).
36. Kalf JG, de Swart BJ, Borm GF, Bloem BR, Munneke M. Prevalence and definition of drooling in PD: a systematic review. J. Neurol. 256(9), 1391-1396 (2009).
37. Miller N, Allcock L, Hildreth AJ, Jones D, Noble E, Burn DJ. Swallowing problems in Parkinson disease: frequency and clinical correlates. J. Neurol. Neurosurg. Psychiatry 80(9), 1047-1049 (2009).
38. Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in PD. Mov. Disord. 6(2), 151-156 (1991).
39. Kaye J, Gage H, Kimber A, Storey L, Trend P. Excess burden of constipation in Parkinson's disease: a pilot study. Mov. Disord. 21(8), 1270-1273 (2006). (Pubitemid 44336628)
40. Krogh K, Ostergaard K, Sabroe S, Laurberg S. Clinical aspects of bowel symptoms in Parkinson's disease. Acta Neurol. Scand. 117(1), 60-64 (2008). (Pubitemid 350264501)
41. Shibata M, Morita Y, Shimizu T, Takahashi K, Suzuki N. Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson's disease. J. Neurol. Sci. 276(1-2), 79-83 (2009).
42. Amantadine. In: American Hospital Formulary Service -Drug Information 2005. McEvoy GK (Ed.). American Society of Health-System Pharmacists, Bethesda, MD, USA, 592 (2005).
43. Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov. Disord. 25(15), 2493-2500 (2010).
44. Goetz CG, Tilley BC, Shaftman SR, et al. on behalf of the Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), scale presentation and clinimetric testing results. Mov. Disord. 23(15), 2129-2170 (2008).
45. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov. Disord. 21(7), 916-923 (2006). (Pubitemid 44184590)
46. Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov. Disord. 22(13), 1901-1911 (2007). (Pubitemid 350134203)
47. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov. Disord. 19(11), 1306-1312 (2004). (Pubitemid 39534547)
48. Perez Lloret S, Pirán Arce G, Rossi M, Caivano Nemet ML, Salsamendi P, Merello M. Validation of a new scale for the evaluation of sialorrhea in patients with PD. Mov. Disord. 22(1), 107-111 (2007). (Pubitemid 46382681)
49. McHorney CA, Bricker DE, Kramer AE, et al. The SWAL-QOL outcomes tool for oropharyngeal dysphagia in adults: I. Conceptual foundation and item development. Dysphagia 15(3), 115-121 (2000). (Pubitemid 30411767)
50. McHorney CA, Bricker DE, Robbins J, Kramer AE, Rosenbek JC, Chignell KA. The SWAL-QOL outcomes tool for oropharyngeal dysphagia in adults: II. Item reduction and preliminary scaling. Dysphagia 15(3), 122-133 (2000). (Pubitemid 30411768)
51. McHorney CA, Robbins J, Lomax K, et al. The SWAL-QOL and SWAL-CARE outcomes tool for oropharyngeal dysphagia in adults: III. Documentation of reliability and validity. Dysphagia 17(2), 97-114 (2002). (Pubitemid 36919838)
52. Agachan F, Chen T, Pfeifer J, Reissman P, Wexner SD. A constipation scoring system to simplify evaluation and management of constipated patients. Dis. Colon Rectum 39(6), 681-685 (1996). (Pubitemid 26181138)
53. Miller N, Allcock L, Hildreth AJ, et al. Swallowing problems in Parkinson disease: frequency and clinical correlates. J. Neurol. Neurosurg. Psychiatry 80(9), 1047-1049 (2009).
54. Lebouvier T, Neunlist M, Bruley des Varannes S, et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One 5(9), e12728 (2010).
55. South AR, Somers SM, Jog MS. Gum chewing improves swallow frequency and latency in Parkinson patients: a preliminary study. Am. Acad. Neurol. 74, 1198-1202 (2010).
56. van der Burg JJ, Didden R, Jongerius PH, Rotteveel JJ. A descriptive analysis of studies on behavioural treatment of drooling (1970-2005). Dev. Med. Child Neurol. 49(5), 390-394 (2007). (Pubitemid 46730693)
57. Arbouw ME, Movig KL, Koopmann M, et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology 74(15), 1203-1207 (2010).
58. Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov. Disord. 17(6), 1318-1320 (2002). (Pubitemid 36041348)
59. Thomsen TR, Galpern WR, Asante A, Arenovich T, Fox SH. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov. Disord. 22(15), 2268-2273 (2007).
60. Praharaj SK, Arora M. Amitriptyline for clozapine-induced nocturnal enuresis and sialorrhoea. Br. J. Clin. Pharmacol. 63(1), 128-129 (2007). (Pubitemid 44902888)
61. Kushnir M, Eilam A, Heldman E. Modafinil reduces drooling in Parkinson's disease. Mov. Disord. 21(Suppl. 13), S598-S599 (2006).
62. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 61(9), 1279-1278 (2003).
63. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 62(1), 37-40 (2004). (Pubitemid 38082867)
64. Postma AG, Heesters M, van Laar T. Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. Mov. Disord. 22(16), 2430-2435 (2007). (Pubitemid 351155992)
65. Meningaud JP, Pitak-Arnnop P, Chikhani L, Bertrand JC. Drooling of saliva: a review of the etiology and management options. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 101, 48-57 (2006). (Pubitemid 41797038)
66. Menezes C, Melo A. Does levodopa improve swallowing dysfunction in Parkinson's disease patients? J. Clin. Pharm. Ther. 34(6), 673-676 (2009).
67. Baijens LW, Speyer R. Effects of therapy for dysphagia in PD: systematic review. Dysphagia 24(1), 91-102 (2009).
68. Restivo DA, Palmeri A, Marchese-Ragona R. Botulinum toxin for cricopharyngeal dysfunction in Parkinson's disease. N. Engl. J. Med. 346(15), 1174-1175 (2002). (Pubitemid 34984614)
69. Born LJ, Harned RH, Rikkers LF, Pfeiffer RF, Quigley EM. Cricopharyngeal dysfunction in Parkinson's disease: role in dysphagia and response to myotomy. Mov. Disord. 11(1), 53-58 (1996). (Pubitemid 26008563)
70. White GN, O'Rourke F, Ong BS, Cordato DJ, Chan DK. Dysphagia: causes, assessment, treatment, and management. Geriatrics 63(5), 15-20 (2008). (Pubitemid 351792196)
71. Nyholm D, Lennernäs H. Irregular gastrointestinal drug absorption in PD. Expert Opin. Drug Metab. Toxicol. 4(2), 193-203 (2008).
72. Barichella M, Cereda E, Pezzoli G. Major nutritional issues in the management of Parkinson's disease. Mov. Disord. 24(13), 1881-1892 (2009).
73. Lertxundi U, Peral J, Mora O, Domingo-Echaburu S, Martínez- Bengoechea MJ, García-Moncó JC. Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease. Am. J. Health Syst. Pharm. 65(5), 414-419 (2008). (Pubitemid 351358342)
74. Friedenberg FK, Parkman HP. Delayed gastric emptying: whom to test, how to test, and what to do. Curr. Treat. Options Gastroenterol. 9(4), 295-304 (2006). (Pubitemid 44131922)
75. Cereda E, Barichella M, Pedrolli C, Pezzoli G. Low-protein and protein-redistribution diets for Parkinson's disease patients with motor fluctuations: a systematic review. Mov. Disord. 25(13), 2021-2034 (2010).
76. Pierantozzi M, Pietroiusti A, Brusa L, et al. Helicobacter pylori eradication and l-DOPA absorption in patients with PD and motor fluctuations. Neurology 66(12), 1824-1829 (2006). (Pubitemid 44049810)
77. Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov. Disord. 12(6), 946-951 (1997). (Pubitemid 27496772)
78. Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov. Disord. 22(9), 1239-1244 (2007). (Pubitemid 47325029)
79. Roarty TP, Weber F, Soykan I, McCallum RW. Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial. Aliment. Pharmacol. Ther. 11(6), 1059-1066 (1997). (Pubitemid 27525096)
80. Chiu CM, Wang CP, Sung WH, Huang SF, Chiang SC, Tsai PY. Functional magnetic stimulation in constipation associated with Parkinson's disease. J. Rehabil. Med. 41(13), 1085-1089 (2009).
81. Simón MA, Bueno AM. Behavioural treatment of the dyssynergic defecation in chronically constipated elderly patients: a randomized controlled trial. Appl. Psychophysiol. Biofeedback 34(4), 273-277 (2009).
82. Rao SS, Valestin J, Brown CK, Zimmerman B, Schulze K. Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial. Am. J. Gastroenterol. 105(4), 890-896 (2010).
83. Ron Y, Avni Y, Lukovetski A, et al. Botulinum toxin type-A in therapy of patients with anismus. Dis. Colon Rectum 44(12), 1821-1826 (2001). (Pubitemid 34031439)
84. Krogh K, Christensen P. Neurogenic colorectal and pelvic floor dysfunction. Best Pract. Res. Clin. Gastroenterol. 23(4), 531-543 (2009).
85. Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson's disease: response to apomorphine. Ann. Neurol. 33(5), 490-493 (1993). (Pubitemid 23143032)
86. Ford B. Pain in Parkinson's disease. Mov. Disord. 25(Suppl. 1), S98-S103 (2010).
87. Stocchi F, Badiali D, Vacca L, et al. Anorectal function in multiple system atrophy and Parkinson's disease. Mov. Disord. 15(1), 71-76 (2000). (Pubitemid 30037990)
88. Norton C, Chelvanayagam S, Wilson-Barnett J, Redfern S, Kamm MA. Randomized controlled trial of biofeedback for fecal incontinence. Gastroenterology 125(5), 1320-1329 (2003). (Pubitemid 37409752)
89. Michelsen HB, Thompson-Fawcett M, Lundby L, Krogh K, Laurberg S, Buntzen S. Six years of experience with sacral nerve stimulation for fecal incontinence. Dis. Colon Rectum 53(4), 414-421 (2010).
90. Hanauer SB. The role of loperamide in gastrointestinal disorders. Rev. Gastroenterol. Disord. 8(1), 15-20 (2008). (Pubitemid 351489694)
91. Salat-Foix D, Andrwes CN, Meddings J, Suchowersky O. Gastrointestinal symptoms in Parkinson disease -clinical aspects and management. Can. J. Neurol. Sci. 38, 557-564 (2011).